|Bid||0.00 x 48300|
|Ask||0.00 x 51100|
|Day's Range||42.35 - 43.10|
|52 Week Range||39.94 - 49.37|
|Beta (5Y Monthly)||0.38|
|PE Ratio (TTM)||33.48|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Jan 25, 2017|
|1y Target Est||47.90|
VENLO, The Netherlands, March 13, 2023--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2022, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here.
QIAGEN (QGEN) will develop a real-time in vitro PCR test that can be utilized to spot IDH1 gene mutations in AML patients in whole blood and bone marrow aspirates.
VENLO, the Netherlands, March 09, 2023--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a strategic partnership with Servier, a global pharmaceutical group, to develop a companion diagnostic test for TIBSOVO®, an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of the blood cancer acute myeloid leukemia (AML).